Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia

Recruiting now

Conditions studied: Pneumonia, Ventilator-Associated

In brief

The goal of this observational study is to show the direct correlation between the occurrence of recurrence of VAP and postagressive immunoparalysis, monitored by HLA-DR rate below litterature-acknowledged threshold, in a well conducted antibiotherapy context, in patient admitted in the Intensive Care Unit. The main questions it aims to answer are: * evaluation of the association between death and persistence of immunoplegia using HLA-DR monitoring * search an association between immunoplegia depth and severity of the initial state of shock * search an association between immunoplegia depth and viral reactivation * compare association of immunoplegia duration and HLA-DR nadir and VAP occurrence Blood samples will be taken from participants to HLA-DR dosage, at the time of inclusion and once a week then.

Key facts

Study ID

NCT06607055

Run by

Centre Hospitalier Intercommunal Aix-Pertuis

People needed

40

Starts

2023-10-04

Expected to finish

2025-09-01

Last updated by the study team

2024-09-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient over 18 years old
• Patient admitted in the Intensive Care Unit of the CHIAP
• Patient under mechanical ventilation
• Patient with infectious pneumonia
• Informed Consent Form (ICF) obtained from the patient or emergency ICF obtained from close relatives
• Patient beneficiary of French social security, whatever the regime

You may not qualify if…

• Patient under 18 years old
• Patient with severe neutropenia (neutrophils < 0.5 G/L)
• Patient under immunosuppressive treatment
• Use of corticosteroids (intravenous or oral) prior to ICU admission
• Use of therapeutic antibodies
• Onco-hematological disease (e.g. lymphoma, leukemia...) under treatment or treated in the 5 years prior to inclusion
• End of chemotherapy 6 months prior to inclusion
• Patients with innate or acquired immune deficiency (e.g., severe combined immunodeficiency, HIV or AIDS, at any stage)
• Patients with a decision to limit or discontinue active therapies, at the time of inclusion
• Patients with an estimated ICU stay of less than 48 hours
• Participation in an interventional study
• Patient deprived of their liberty
• Patient under tutorship or curatorship
• Pregnant or breastfeeding woman

Where it is running

• Centre Hospitalier Intercommunal Aix-Pertuis — Aix-en-Provence, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.